Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Monday 30 January, 2006

XTL Biopharm Ltd

Presentation at the Bean Murray Conference


    XTL Biopharmaceuticals to Present at the Brean Murray, Carret Small Cap    
                       Institutional Investor Conference                       

NEW YORK, Monday, January 30, 2006: XTL Biopharmaceuticals, Ltd. (Nasdaq: (LSE:
XTL ; NASDAQ: XTLB ; TASE: XTL), a biopharmaceutical company developing drugs
against hepatitis, announced today that Ron Bentsur, Chief Executive Officer,
will present an overview of the Company at The Brean Murray, Carret Small Cap
Institutional Investor Conference in New York City. Mr. Bentsur's presentation
will take place on Wednesday, February 1, 2006 at 11:30 a.m. Eastern Time at
the Grand Hyatt New York Hotel. A live audio webcast of Mr. Bentsur's
presentation will be available at http://www.wsw.com/webcast/bmry2/xtl/ . An
archived version of the webcast will be available following the conclusion of
the live presentation.

Contact:
Ron Bentsur, Chief Executive Officer Tel: +1-212-531-5971

About XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd. ('XTLbio') is engaged in the research, development
and commercialization of therapeutics for the treatment of infectious diseases;
with a primary focus on hepatitis C. XTLbio's most advanced therapeutic in
Hepatitis C is XTL-6865 - a combination of two monoclonal antibodies against
the hepatitis C virus - presently in Phase 1 clinical trials in patients with
chronic hepatitis C.  XTLbio's second Hepatitis C therapeutic is XTL-2125 - a
small molecule inhibitor of the hepatitis C virus polymerase - expected to
enter Phase 1 clinical trials in 1H2006.  XTLbio hepatitis C pipeline also
includes several families of pre-clinical hepatitis C small molecule
inhibitors.  In addition, XTL has out-licensed to Cubist Pharmaceuticals an
antibody therapeutic against hepatitis B, HepeX-B, which has recently completed
a Phase 2b clinical study in transplant patients.  XTLbio is publicly traded on
the London, NASDAQ, and Tel-Aviv Stock Exchanges (LSE: XTL; NASDAQ: XTLB; TASE:
XTL).


                                              

a d v e r t i s e m e n t